Recipharm completes acquisition of Sanofi inhalation contract manufacturing business

Recipharm and Sanofi have completed the acquisition of Sanofi’s inhalation contract manufacturing business including a manufacturing facility located in Holmes Chapel, UK.

The facility, which includes development and manufacturing capabilities for novel respiratory products, complements the inhalation development expertise offered by the Recipharm team in Research Triangle Park, North Carolina. 

Announced in June 2018, the acquisition forms part of Recipharm’s M&A growth strategy, which is focused on expanding its full service offering to include specialist, in-demand capabilities.

Commenting on the announcement, Thomas Eldered, CEO of Recipharm said: “Treatments for asthma and chronic obstructive pulmonary disease (COPD) are in high demand and are therefore key growth areas for our business”.

“This new capability allows us to expand our offering to customers developing novel respiratory products by adding additional expertise and manufacturing capacity to Recipharm. We look forward to growing this side of our business and continuing to enhance our wider development services offering.”

The Holmes Chapel manufacturing facility is one of the leading sites of its type in Europe and is home to a team of more than 450 specialist employees.

The prime technologies manufactured at the facility include metered dose inhalers and nasal sprays. It also houses several development suites specifically for dry powder and other inhalation technologies.

For more information on Recipharm’s inhalation and nasal product development services, visit: https://www.recipharm.com/development/inhalation-and-nasal-product-development

Recipharm will be exhibiting at CPhI Worldwide in Madrid. Visit stand 3D50.

For more information please visit www.recipharm.com or contact:
Thomas Eldered, CEO, telephone: +46 8 602 52 10
Karl Lindström, CFO, telephone: +46 8 602 53 11, ir@recipharm.com

This information is information that Recipharm AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, on 01 October 2018, at 16:00 CET.

About Recipharm
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing around 5,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm’s turnover is approximately SEK 6.0 billion and the Company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.

For more information on Recipharm and our services, please visit www.recipharm.com